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Introduction
The dual-enrolling of phase 1 volunteers is a potential risk to subjects. It can
also distort study results, threaten study validity, and may cause harm to future
patients. Existing subject registries differ in structure, funding, and governance.
While the choice of the ideal system is driven by the scope of the risk, funding
mechanism, and is ultimately a value judgment of freedom vs. paternalism, none
of the registries significantly impinges on the tenets of ethically based research.

The Belmont report, issued in 1978 by the National Commission for the
Protection of Human Subjects of Biomedical and Behavioral Research, identified
key pillars of ethical research to be justice, autonomy and beneficence. A key
principal is that human subject research has a responsibility to minimize harm
and maximize benefit for participants as long as there is acceptable equipoise.
There is, however, no absolute requirement of potential benefit for participation
for even those with disease.

For example, while oncologists and patients

participate in phase 1 oncology trials with a primary hope for therapeutic
response, a primary goal of these studies is not necessarily drug efficacy. The
lack of understanding of the distinction by patients is well described. Other study
designs, such as those of non-inferiority or comparative effectiveness, do not
provide patients with a direct benefit of participation, outside of access to care
and or financial compensation.

Healthy volunteer studies entail risk, with no

potential for therapeutic benefit to participants. The lack of any potential health

benefit outside of an evaluation of health status has often led to heightened
Institutional Review Board (IRB) scrutiny for phase 1 studies.

The focus of

regulation in healthy volunteer clinical trials is typically of the short-term
protection of subjects from harm directly related to study procedures. Outside of
cumulative limits on radiation exposure, the role of the subject outside of an
individual trial is generally not considered. The National Institutes of Health and
Federal Drug Administration do not strictly limit the number of studies in which a
volunteer can participate.

It is suggested merely that subjects should not

consecutively enroll in studies without adequate time for washout of drug or
intervention based upon the biology of the system. Recent attention, however,
has been raised about the potential of phase 1 volunteer participants to enroll in
multiple concurrent clinical trials, with calls for a mandatory registry to track
subjects.(1)

Motivations for healthy volunteer participants in clinical research can be altruistic,
especially for disease-specific activists or those with afflicted family members.
For the most part, however, the prime motivation for most phase 1 trial enrollees
who lack of an underlying disease is in the financial compensation for
participation.(2,3) Pursuit of compensation can incentivize subjects to enroll in
multiple studies, despite the potential for personal injury, or risk of discovery and
loss of access to participate at research sites. The ease of access to clinical
research unit web sites which list study calendars, and user-generated
publications allows subjects to remotely plan participation and allow overlap while

minimizing study procedure conflict and detection by a clinical research site.
Because of the ease of access, enrolling in more than one study at a time is a
problematic issue not only for the sites to identify but also for the safety of
individual subjects. Multiple enrollment introduces occult bias, primarily by an
increased incidence of adverse events and drug interactions which may alter
pharmacokinetic or pharmacodynamic endpoints.

These potential drug

interactions also clearly increase the personal risk for healthy study subjects.
The loss of study validity could be seen by subjects in a narrow sense only
harming a commercial sponsor without larger implications. However, outside of
the personal risk subjects take on from dual enrolling, the practice entails
potential to harm future patients. In the worst case, the unwarranted maligning of
a drug due to an undisclosed drug interaction could delay the advancement of
promising drug candidates, or place restrictions on future use.

Investigating

adverse events or unexpected results caused by dual enrolling utilizes
investigator and sponsor resources and is a friction upon the system that detracts
from the development of other drugs.

A number of countries have approached the problem of dual enrollment in a
variety of ways. (Table)

Models have included mandatory government-run

programs, such as those in France, and the Southern Swiss Canton of Ticino,
non-profit voluntary systems such as the TOPS system in the UK, and private
sector for profit vendors in the United States and Canada. In a retrospective
three-year study done by clinical researchers in Southern Switzerland, where

there is a current register in place, repeat volunteerism in their registered
population (N=1436) was only 0.2%.(4) This regional registry mandates a
minimum of three-month drug-free interval.

A German survey of healthy

volunteers (N=440) reported dual enrollment rate of ~3%. In a US survey of 60
subjects, ten percent admitted to being dually enrolled in studies.(2) The most
common motivation in all these reports was financial.

In contrast, the North

American registry provider IDI/Clinical RSVP reports a 12-18% rate of screening
attempts before an appropriate wash out period.

A potential argument against a central registry can be assessed in terms of
justice, subject autonomy and cost. The primary potential harm to subjects is
that of loss of privacy. For the governmentally mandated programs in locales
with centralized medical care delivery, the risk of data breech is not significantly
more than that associated with the standard delivery of medical care. The UK
and North American systems, which collect limited subject data, have even less
potential risk for confidential data release. Recent history of large-scale data
breeches in various industries suggests that the potential for inadvertent release
of clinical trial data private and governmental databases is equally likely. The
relative cost of administering a government-sponsored central registry can be
viewed as an added cost to the clinical trial enterprise carried by society as a
whole, or in a directed funding model, by the trial sponsors and research units.
In the voluntary, private service model, the cost is borne by the users of the
system. However, as a primarily market-driven initiative, the value of a registry

for sites and sponsors can be made on a business calculus of the relative cost of
ensuring patient safety and trustworthy data.

In North America and the UK,

subjects are free to limit participation to research sites that do not participate in
central registries. However, even in mandatory systems of France and Ticino,
the use of a centralized registry is not coercive, and autonomy of subjects is
maintained. While the use of registries that collect even limited information may
dissuade subject participation in studies, the practice does not impinge on the
ability of subjects to make informed decisions about participation. Indeed, the
ability to volunteer in healthy volunteer studies is not a right.

By definition,

potential subjects do not have a disease state for which treatment is needed.

The third Belmont principal is that of beneficence. Broadly stated, the questions
are 1) is there a need to protect clinical trial subjects from themselves, and 2) is
the subject’s attestation that they were not dually enrolled adequate evidence to
ensure their protection? The relative risks from loss of confidentiality are small,
being equal or less to that associated with routine medical care. The relative
risks of dual enrolling to subjects are difficult to assess. Despite the catastrophic
TeGenero incident in 2006, in which healthy volunteers had grave injury during a
first in human investigation of the drug TGN1412,, and a number of scattered
individual events, on the whole participation in phase 1 clinical trials is not
particularly dangerous.(5) While there are limited central data to make
quantitative assessments of risk, participation in phase 1 studies according to
study protocol almost certainly poses less risk than many accepted sources of

income in our society such as police, fire fighters, and construction workers. The
poor evidentiary base of data makes an assessment of the additional risk from
dual enrolling impossible to make with precision. Accordingly, using standard
methods to place a dollar cost per event prevented is not possible. Against this
backdrop of uncertainty however, it is in the interest of sponsors to conduct the
best studies possible. This includes not only the fiduciary duty to ensure high
quality data, but also in making reasonable efforts to maximize the safety of
subjects.

Stakeholders in this process include not only sponsors, but also

contract research organizations and site investigators. Subject education and
systems to promote it will clearly not prevent all dual enrollment, but should be
considered important elements of the informed consent process.

The key question is whether the risk to subjects justifies the cost to the research
enterprise (both private and public) of a mandatory registry. Of note, the need for
a registry has not been identified by the Department of Health and Human
Services in the recently proposed overhaul of human subjects protection policies.
We argue that the evidence of risk to subjects from occult dual enrolling is not
high enough in relation to cost and to a lesser extent, potential loss of privacy, to
warrant a mandatory system. While it has been proposed that the FDA or NIH
could administer a mandatory registry, neither organization has expressed an
interest in pursuing this. Establishing and maintaining a mandatory model would
take resources, which in the current budgetary climate would involve moving
funding from other core missions of these federal agencies. There is, however,

no ethical conflict with the establishment of a voluntary system to prevent dual
enrollment. A voluntary system is maximally efficient with dense adoption of a
single registry, which prevents dual enrollers seeking research units without
registry verification. This could result in differential enrollment and adverse event
patterns at otherwise comparable sites. Non-sponsor owned sites, which choose
to voluntarily participate in a registry, without explicit sponsor assumption of
costs, also put themselves at competitive disadvantage when bidding for studies.
In aggregate, however, a voluntary system has the benefit of spreading costs to
the users of the system, as well as preserving the right of subjects to participate
at research sites not participating in the system.

Modern evidence based

medicine and drug development are based upon the use of high quality data to
make cost benefit analysis. While the lack of evidence of benefit of a phase 1
subject registry should not prevent the phase 1 trial community from acting, the
uniform institution of a mandate for subject registries is not yet supported by the
extant data.
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Table: Phase 1 Registries
Database

Who enrolls

Southern.
Switzerland
Regional
Registry

Healthy
volunteers

United
Kingdom/
TOPS

Site
participation
mandatory

Healthy
volunteers for
Phase 1 trials.
Site
participation
voluntary.

France

Exclusion/
washout
period
PI dependent,
at least 3
months

Subjects in
whom research
has no direct
benefit
Site
participation

Systemic drugs
- 3 months
min;
-cannot receive
> 10 milli-Sv
of radioactivity
in any 12-mo
pd

PI dependent

Data Collection

Strengths /
Benefits

Weaknesses /
Risks

Volunteer code
(initials+ DOB +
gender+
nationality),
clinical research
unit, study name,
and date that
subject’s allowed
to participate
again in another
trial

If subject caught,
they are excluded
from all future
studies. Only
those involved
with study can
access
information; no
other sites.
Subject identity
protected on
computer with no
network access
and alarm system.
De-identified data.
Site has flexibility
with trials that
have long follow
up (>4wks).
Simple, webbased interphase

Subject cannot
refuse to be on
registry.

Data purge 1 year
after the last date
is entered.

Based on annual
salary ($4000
annually).
No protection
against ID theft,
privacy.

Data purge after 5
yrs.
Unique ID
(national
insurance # or UK
citizens or
passport # at
screening and the
date of last dose
of study drug
Data purge after 2
yrs.
Code derived
from subject’s
names/DOB;
start/end dates of
study; end date of
exclusion pd; $
compensation

Usernames and
password protected
by authorized users
Input errors require
calls to other sites
to clarify
participation
history

Multi-Site
Viewing of
Information?
No

Cost

Regulator

Government

Swiss
National
Science
Foundation

Financed by
exam/appro
val
fees~500
Swiss
Francs/stud
y

Web-based and
all authorized
CRUs can
share/view if a
subject has
registered but not
the last dose day
(they must call
the CRU)
All authorized
research centers
have direct
access

Registered
non-profit
organization
Free to
sites.

Government
Public
finance

The
individual
site and
TOPS
Administrat
ion

Ministry of
Health

mandatory

USA &
Canada/
ClincalRSVP

Any subject
who receives
compensation
for trial

Subject must show
proof of national
health insurance

PI/study
dependent

Data purge after 5
yrs.

Site
participation
voluntary

USA &
Canada/
Verified
Clinical
Trials

Any subject
who receives
compensation
for trial
Site
participation
voluntary

Biometric data
(finger print
code), last dose

Subjects can
dispute
information
entered into
database if not
accurate.
Transparent
tracking and
auditing

PI/study
dependent

Web-based portal

Limited collection
of subject data.
Validity of subject
identification
checked against
publically
available
databases

Voluntary basis
allows subjects to
seek nonparticipating sites
when dual enrolling

Sites can view
only last date of
study drug
administration

Effectiveness
reduced unless
many sites in a
region participate

Voluntary basis
allows subjects to
seek nonparticipating sites
when dual enrolling

Private
Sector

Private
corporation

Training +
install =
~$1500
$40 per
subject/stud
y

Sites can view if
subject is eligible

Effectiveness
reduced unless
many sites in a
region participate

PI = Principal Investigator; DOB = date of birth; TOPS = The Over volunteering Prevention System; CRU = clinical research unit.

$500 per
study

Private
corporation

